Plexision Awarded Competitive Grant from the National Science Foundation for COVID-19 Immunity Test Development | Plexision
Summary
Plexision has been awarded a National Science Foundation (NSF) Phase 1 Small Business Innovation Research Grant. The blood test measures cell-mediated immunity to the SARS-CoV-2 coronavirus. It allows medical providers to assess the risk of COVID-19 infection, the blood test also identifies if a patient is at risk for a severe infection. Now more than ever medical providers across the globe are in need of the necessary tools to combat this virus and assist in patient treatment plans, Plexisions technology is doing just that! By allowing medical professionals to get the upper hand on a patients infection risk physicians will now be able to recommend appropriate preventative measures and if needed plan accordingly to limit progression in those already infected.To read more please visit the following link: www.businesswire.com